Gsa Capital Partners LLP Atea Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.19 Billion
- Q1 2024
A detailed history of Gsa Capital Partners LLP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 19,071 shares of AVIR stock, worth $69,990. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,071
Previous 149,878
87.28%
Holding current value
$69,990
Previous $457,000
83.15%
% of portfolio
0.01%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding AVIR
# of Institutions
119Shares Held
49.6MCall Options Held
108KPut Options Held
327K-
Black Rock Inc. New York, NY9.24MShares$33.9 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.15MShares$22.6 Million0.71% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.54MShares$20.3 Million14.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$17.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.08MShares$15 Million2.01% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $306M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...